tiprankstipranks
Trending News
More News >
Xilio Therapeutics Inc (XLO)
NASDAQ:XLO
US Market

Xilio Therapeutics (XLO) Income Statement

Compare
212 Followers

Xilio Therapeutics Income Statement

Last quarter (Q3 2025), Xilio Therapeutics's total revenue was $19.07M, an increase of 1005.92% from the same quarter last year. In Q3, Xilio Therapeutics's net income was $-16.29M. See Xilio Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 6.34M$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 6.34M$ 0.00$ 0.00$ -1.50M$ -1.06M
Operating Expenses
$ 66.93M$ 79.13M$ 89.15M$ 73.55M$ 53.50M
Depreciation and Amortization
$ 1.64M$ 1.90M$ 1.85M$ 1.50M$ 1.06M
EBITDA
$ -58.00M$ -77.23M$ -87.30M$ -73.70M$ -53.55M
Operating Income
$ -60.58M$ -79.13M$ -89.15M$ -75.04M$ -54.56M
Other Income/Expenses
$ 2.34M$ 2.73M$ 927.00K$ -756.00K$ -656.00K
Pretax Income
$ -58.24M$ -76.40M$ -88.22M$ -75.80M$ -55.22M
Net Income
$ -58.24M$ -76.40M$ -88.22M$ -75.80M$ -55.22M
Per Share Metrics
Basic EPS
$ -1.09$ -2.78$ -3.19$ -2.72$ -2.01
Diluted EPS
$ -1.09$ -2.78$ -3.19$ -2.72$ -2.01
Weighted Average Shares Outstanding
53.51M 27.50M 27.39M 27.36M 27.47M
Weighted Average Shares Outstanding (Diluted)
53.51M 27.50M 27.39M 27.36M 27.47M
Currency in USD

Xilio Therapeutics Earnings and Revenue History